Full Text View
Tabular View
No Study Results Posted
Related Studies
Cetuximab and Lenalidomide in Head and Neck
This study is ongoing, but not recruiting participants.
Study NCT01133665   Information provided by University of Chicago

First Received on May 27, 2010.   Last Updated on June 21, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Squamous Cell Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Interventions listed in this trial
Cetuximab and Lenalidomide
Additional drug interventions recognized in this trial
Cetuximab
Lenalidomide
Thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Chicago
Celgene Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services